G3BP2

Ras GTPase-activating protein-binding protein 2 · Q9UN86 · G3BP2 on Sugi Atlas →

0 patent compounds predicted against G3BP2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to G3BP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 PHASE2COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation PHASE1/PHASE2RECRUITING
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer PHASE1/PHASE2COMPLETED
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas PHASE1COMPLETED
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Gemcitabine and Dasatinib in Advanced Solid Tumors PHASE1COMPLETED
Expression and Function of the Renin-Angiotensin System in the Esophagus EARLY_PHASE1COMPLETED
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN
Long Term Prediction of MASH-related HCC Risk by Proteomics nanNOT_YET_RECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer nanRECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma nanCOMPLETED
MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma nanCOMPLETED
Solid Tumors in RASopathies nanRECRUITING
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a G3BP2 binder may also engage these)

ProteinNameSimilarity
Q5R9L3 1.000 Q5R9L3 →
P97379 1.000 P97379 →
Q32LC7 1.000 Q32LC7 →
P97855 0.999 P97855 →
G3BP1 Ras GTPase-activating protein-binding protein 1 0.998 landscape →
Q5RB87 0.997 Q5RB87 →
EIF4B Eukaryotic translation initiation factor 4B 0.961 landscape →
Q8BGD9 0.957 Q8BGD9 →
Q0VFL7 0.956 Q0VFL7 →
HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2 0.954 landscape →
YTHDF1 YTH domain-containing family protein 1 0.953 landscape →
P19600 0.953 P19600 →
SF3A1 Splicing factor 3A subunit 1 0.953 landscape →
O77768 0.952 O77768 →
Q9Z204 0.951 Q9Z204 →
G3V9R8 0.951 G3V9R8 →
YTHDF3 YTH domain-containing family protein 3 0.950 landscape →
Q9WU01 0.949 Q9WU01 →
Q5RA82 0.948 Q5RA82 →
Q8BYK6 0.948 Q8BYK6 →
Q9P2N5 0.948 Q9P2N5 →
KHDRBS1 KH domain-containing, RNA-binding, signal transduction-associated protein 1 0.947 landscape →
P59326 0.947 P59326 →
Q8BTF8 0.947 Q8BTF8 →
Q9UKM9 0.947 Q9UKM9 →
Q5R5W2 0.946 Q5R5W2 →
Q2YDP3 0.946 Q2YDP3 →
Q920F3 0.946 Q920F3 →
Q64012 0.946 Q64012 →
Q8CGC4 0.946 Q8CGC4 →